Iterum Therapeutics plc

NasdaqCM ITRM

Iterum Therapeutics plc Market Capitalization on January 14, 2025: USD 44.03 M

Iterum Therapeutics plc Market Capitalization is USD 44.03 M on January 14, 2025, a 30.82% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Iterum Therapeutics plc 52-week high Market Capitalization is USD 83.20 M on December 04, 2024, which is 88.99% above the current Market Capitalization.
Iterum Therapeutics plc 52-week low Market Capitalization is USD 20.67 M on October 09, 2024, which is -53.04% below the current Market Capitalization.
Iterum Therapeutics plc average Market Capitalization for the last 52 weeks is USD 31.65 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: ITRM

Iterum Therapeutics plc

CEO	Mr. Corey N. Fishman
IPO Date	May 25, 2018
Location	Ireland
Headquarters	Fitzwilliam Court
Employees	14
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Key trends

Past 5 years